Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Desmond Curran

Showing results (21-30 of 85) with videos related to

Pageof 9
Sort By:
Infectious Diseases and Therapy|November 26, 2024
Modelled Public Health Impact of Introducing Adjuvanted Recombinant Zoster Vaccine into the UK National Immunisation ProgrammeManjit Hunjan, Desmond Curran, Alen Marijam, et al.
Joint Bone Spine|April 10, 2010
Epidemiology of osteoporosis-related fractures in France: a literature reviewDesmond Curran, Milka Maravic, Philippe Kiefer, et al.
Human Vaccines & Immunotherapeutics|November 15, 2023
Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studiesAgnes Mwakingwe-Omari, Nicolas Lecrenier, Abdi Naficy, et al.
The Pediatric Infectious Disease Journal|February 3, 2016
Vaccine Timeliness: A Cost Analysis of the Potential Implications of Delayed Pertussis Vaccination in the USDesmond Curran, Augustin Terlinden, Jean-Etienne Poirrier, et al.
Infectious Diseases and Therapy|May 21, 2025
The Potential Impact of Increased Recombinant Zoster Vaccine Uptake in Older Adults WorldwideNikolaos Giannelos, Desmond Curran, Sean Matthews, et al.
Infectious Diseases and Therapy|June 19, 2024
The Incidence of Herpes Zoster Complications: A Systematic Literature ReviewNikolaos Giannelos, Desmond Curran, Chi Nguyen, et al.
Vaccine|February 27, 2025
Corrigendum to "The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 years" [Vaccine 41 (37) (23 August 2023) 5360-5367]David Singer, Ahmed Salem, Nikita Stempniewicz, et al.
Vaccine|August 4, 2023
The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 yearsDavid Singer, Ahmed Salem, Nikita Stempniewicz, et al.
Human Vaccines & Immunotherapeutics|July 26, 2021
Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in BeijingChrista Lee, Ning Jiang, Haiwen Tang, et al.
BMC Infectious Diseases|October 5, 2018
Impact of herpes zoster and postherpetic neuralgia on the quality of life of Germans aged 50 or aboveDesmond Curran, Ruprecht Schmidt-Ott, Ulf Schutter, et al.
Pageof 9

Showing results (21-30 of 85) with videos related to

Sort By:
Pageof 9
Infectious Diseases and Therapy|November 26, 2024
Modelled Public Health Impact of Introducing Adjuvanted Recombinant Zoster Vaccine into the UK National Immunisation ProgrammeManjit Hunjan, Desmond Curran, Alen Marijam, et al.
Joint Bone Spine|April 10, 2010
Epidemiology of osteoporosis-related fractures in France: a literature reviewDesmond Curran, Milka Maravic, Philippe Kiefer, et al.
Human Vaccines & Immunotherapeutics|November 15, 2023
Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studiesAgnes Mwakingwe-Omari, Nicolas Lecrenier, Abdi Naficy, et al.
The Pediatric Infectious Disease Journal|February 3, 2016
Vaccine Timeliness: A Cost Analysis of the Potential Implications of Delayed Pertussis Vaccination in the USDesmond Curran, Augustin Terlinden, Jean-Etienne Poirrier, et al.
Infectious Diseases and Therapy|May 21, 2025
The Potential Impact of Increased Recombinant Zoster Vaccine Uptake in Older Adults WorldwideNikolaos Giannelos, Desmond Curran, Sean Matthews, et al.
Infectious Diseases and Therapy|June 19, 2024
The Incidence of Herpes Zoster Complications: A Systematic Literature ReviewNikolaos Giannelos, Desmond Curran, Chi Nguyen, et al.
Vaccine|February 27, 2025
Corrigendum to "The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 years" [Vaccine 41 (37) (23 August 2023) 5360-5367]David Singer, Ahmed Salem, Nikita Stempniewicz, et al.
Vaccine|August 4, 2023
The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 yearsDavid Singer, Ahmed Salem, Nikita Stempniewicz, et al.
Human Vaccines & Immunotherapeutics|July 26, 2021
Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in BeijingChrista Lee, Ning Jiang, Haiwen Tang, et al.
BMC Infectious Diseases|October 5, 2018
Impact of herpes zoster and postherpetic neuralgia on the quality of life of Germans aged 50 or aboveDesmond Curran, Ruprecht Schmidt-Ott, Ulf Schutter, et al.
Pageof 9